From what 15 stock analysts predict, the share price for Illumina Inc (ILMN) might increase by 10.39% in the next year. This is based on a 12-month average estimation for ILMN. Price targets go from $85.00 to $258.00. The majority of stock analysts believe ILMN is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
ILMN is a stock in Health Care which has been forecasted to be worth $154.60 as an average. On the higher end, the forecast price is $258.00 USD by conor mcnamara from RBC Capital and on the lower end ILMN is forecasted to be $85.00 by luke sergott from Barclays.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
patrick b donnelly Citi | Hold | $145.0 | reiterated | Feb 9, 2024 |
daniel brennan TD Cowen | Hold | $150.0 | maintained | Feb 8, 2024 |
catherine ramsey schulte Robert W. Baird | Hold | $144.0 | maintained | Jan 29, 2024 |
kyle mikson cfa Canaccord Genuity | Hold | $130.0 | maintained | Jan 16, 2024 |
shubhangi gupta HSBC | Hold | $150.0 | downgraded | Jan 15, 2024 |
eve burstein Bernstein | Hold | $127.0 | upgraded | Dec 15, 2023 |
john sourbeer UBS | Hold | $111.0 | maintained | Nov 10, 2023 |
rachel vatnsdal J.P. Morgan | Hold | $110.0 | maintained | Nov 10, 2023 |
dan leonard Credit Suisse | Hold | $200.0 | rated | Aug 9, 2023 |
tejas savant Morgan Stanley | Hold | $225.0 | maintained | Apr 26, 2023 |
julia qin J.P. Morgan | Hold | $235.0 | maintained | Apr 26, 2023 |
tycho peterson J.P. Morgan | Hold | $235.0 | maintained | Apr 26, 2023 |
jasper hellweg Argus Research | Hold | None | downgraded | Jan 25, 2023 |
derik de bruin Bank of America Securities | Hold | None | maintained | Sep 2, 2022 |
lorenzo biasio Credit Suisse | Hold | $270.0 | maintained | Aug 17, 2022 |
james mainwaring Atlantic Equities | Hold | $390.0 | downgraded | Mar 31, 2021 |
mark massaro BTIG | Hold | $310.0 | maintained | Oct 24, 2019 |
amanda murphy BTIG | Hold | None | downgraded | Jan 5, 2018 |
paul knight KeyBanc | Hold | None | upgraded | Oct 23, 2017 |
dane leone Raymond James | Hold | None | rated | Mar 16, 2017 |
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
When did it IPO
2000
Staff Count
10,590
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Mr. Jacob Thaysen Ph.D.
Market Cap
$22.79B
In 2023, ILMN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ILMN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
EBAY-USD
$43.8
FITB-USD
$33.49
ALGN-USD
$316.56
$199.73
$1523.19
PTC-USD
$178.19